IP Library Granted Patent US 9,243,227
Granted Patent B2
US 9,243,227 · App. 13/431,542 · Granted Jan 26, 2016

Cytotoxic T lymphocyte

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,243,227
App. No.
13/431,542
Granted
Jan 26, 2016
Kind
B2
Abstract

The present invention relates to a T lymphocyte having an activity to induce a T lymphocyte recognizing an antigen and a technique to use the T lymphocyte.

Claims (14)

1. A method for inducing a T lymphocyte, comprising:

transducing a T lymphocyte with an RNA encoding an antigen of interest, wherein said T lymphocyte comprising the transduced RNA functions as an antigen-presenting cell;

treating the T lymphocyte transduced with the RNA by gamma ray irradiation or with mitomycin; and

stimulating a T lymphocyte with the T-lymphocyte transduced with the RNA obtained in the above step, thereby inducing the T lymphocyte which recognizes the antigen.

2. The method according to claim 1 , wherein the T lymphocyte transduced with the RNA is a CD4-positive cell.

3. The method according to claim 1 , wherein the T lymphocyte which recognizes the antigen is a cytotoxic T lymphocyte positive to CD8.

4. The method according to claims 1 , wherein the antigen is a tumor-associated antigen or an antigen of an infectious microorganism.

5. The method according to claim 4 , wherein the RNA is an RNA prepared from a cancer tissue.

6. The method according to claim 4 , wherein the antigen is EBNA3A and/or CMVpp65.

7. The method according to claim 1 , wherein the T lymphocyte transduced with the RNA is activated with phytohemagglutinin.

8. The method according to claim 1 , which further comprises the process of proliferating the induced T lymphocyte.

9. The method of claim 1 , wherein the antigen of interest is selected from the group consisting of MAGE-A4, SAGE, LAGE, WT-1, and hTERT.

10. The method of claim 1 , wherein the antigen of interest is MAGE-A4.

11. The method of claim 1 , wherein the antigen of interest is SAGE.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 29, 2019
From: TAKARA BIO INC.
To: MIE UNIVERSITY
Reel/Frame 050213/0980 →
CHANGE OF ADDRESS Recorded Jun 24, 2016
From: TAKARA BIO INC.
To: TAKARA BIO INC.
Reel/Frame 039152/0834 →